MAB

Bionaturis launches today its capital increase

The negotiation period is between 9th until 15th June, both inclusive
The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

Jerez, June 9th 2015. The Board of Directors of Bolsas y Mercados Españoles (BME) has agreed the listing from today Tuesday and until next Monday, June 15th, both inclusive, 4.633.036 preferential subscription rights of the Bionaturis Group that will be negotiated in the Alternative Equity Market (MAB) under the code (BNT.D).

The rights negotiation of the new Bionaturis shares falls within the subscription period, which is scheduled4th July to be over. Once completed it and if there is any shares left, discretionary assignment period will be open to place the remaining shares to other investors.

This capital increase, approved last week by the governing body of the MAB, aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share. If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a […]

June 9th, 2015|Blog english, Press Releases|Comments Off|

Approved the Bionaturis Group Capital Increase for a maximun of up to 579.129 new shares

The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

After the acquisition Bionaturis Group would have a global turnover over €8 Million in the year 2016, with an EBITDA’s operating margin about 30% and employing more than 60 workers, strengthening the Group’s industrial structure.

The Company carried out another capital increase operation last April 2014 for an amount worth of €3 Million with 76% of oversubscription.

Jerez, on June 2, 2015. The Alternative Equity Market (MAB) Governing Body has approved the Document of Capital Increase (Spanish DAM) presented by Bionaturis Group in order to formalize the capital increase operation authorized by its Board of Directors last May, 14 2015. This capital increase aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share.

If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a par value of €0,05 each one.

The new issued shares will trade in MAB as soon as […]

June 2nd, 2015|Blog english, Press Releases|Comments Off|

Bionaturis shares start quoting in the continuous system on the MAB

Shares of Bionaturis (BNT-MB), an international reference company developing biological drugs, will start quoting from next 23 June in the continuous system instead of fixing (with two auctions per day) on the MAB. So that, Bionaturis’ shares will be available to buy and sell at any moment of each trading session.

It´s a new achievement after its recent increase of capital with 76% of oversubscription. Since its opening session on the MAB, BNT shares price has increased 330%, while the liquidity of the value has increased progressively.

According to Victor Infante, Bionaturis’ CEO, “this is a new milestone on our path in response to what investors were asking for. We have confidence that this measure will allow new qualified stakeholders who understand the business and want to make history with us to be on board. Trading by the continuous system means opening the door to specialized investment funds, both national and abroad, that will contribute to consolidate our growth”.

 

Bionaturis takes part in the MedCap Forum

As previous years Bionaturis (ticker BNT) will take part in the Medium Capitalization Companies Forum, organized by Bolsas y Mercados Españoles (BME) that celebrates on 27 and 28 May its tenth edition. This meeting has the aim of  fostering the liquidity and financial standing of these companies that are listed on Spanish Stock Markets.

Our CEO, Víctor Infante, will represent Bionaturis at the  private meetings  with investors that will take place in the Palacio de la Bolsa (Madrid). Infante has stated: “Meetings like these are very useful to keep a direct contact with our current and future investors, and other companies listed on financial markets as well. It´s a good opportunity for the MAB to show off its outstanding progression”.

Besides Bionaturis, the MAB will be represented by other top-perform companies such as Carbures and Gowex, among others.

For further information, please click here

Bionaturis’ new shares will start quoting at April 30

The Spanish Alternative Stock Market (MAB, in Spanish) has informed about the starting of quotation of Bionaturis’ new issued shares as a result of the just-finished capital increase.

441.241 new shares will be trading in a record time since the ending of the capital increase last April 24. The operation was fulfilled with an oversubscription of 76%.

For further information, please click here  

Bionaturis fulfilled its 3 million € increase of capital with oversubscription

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has managed to raise 3.088.687 €, 100% of the recent increase of capital offer. It´s noteworthy that there has been an oversubscription of 76% of the total new issued shares. As a result, 441.241 new shares of a nominal value of 0.05 € each, plus an issue premium of 6.95 € have been subscribed.

It´s important to note that 74% of the final subscription has been issued by old shareholders.

After completing the process, Victor Infante, Bionaturis CEO has stated “from start to finish the whole process has surpassed our expectations. Oversubscription of 76%, the confident of old shareholders and the great potential of the new ones, even the negotiation during the pre-emptive subscription rights in the MAB have been overwhelming. On behalf of all the team we just want to say thank you for trusting in Bionaturis. This proof of confidence encourages us to implement successfully our expansion plan. We will release good news in this sense shortly.”

Purpose of the capital increase

The purpose of the capital increase is to finance the company´s internationalization plan and to undertake further investments.

 

April 24th, 2014|Press english|0 Comments|

Bionaturis pushes the MAB in its rise of 2014

Bionaturis, quoting on the Spanish MAB since January 2012, is one of the companies that are contributing to the Spanish Alternative Stock Market to continue getting records in this new year. During the two months and some days sessions of 2014, the MAB has overtaken all the trading volume of 2013 –considered its take off year- with 278.67 million euros.

Bionaturis peaked its maximum ever last 26th February, reaching 11 euros. After the first two months of 2014, the company has also surpassed the whole trading volume of 2013. Nowadays, it’s one of the stock assets with more profitability and liquidity of this specific market made up of small cap enterprises looking to expand.

For this 2014, the company expects an increasing of its annual turnover in more than 400%.

The general trend in the sector, increasing

The biotechnology sector ended 2013 as the most profitable value in the stock market index with 53.96%. The trend keeps growing in the first weeks of the new year.
Opinion leaders say that it is a sector in expansion around the world with strong links in other areas such as agriculture, the environment and energy. In particular, the biotech sector presents technical and scientific conditions adequate to continue capturing investment also in Spain. This trend is having its pair in Spain, where biotech companies that are quoted on the MAB as AB BIOTICS, NEURON, 1NQUEMIA or BIONATURIS have increased their market capitalization value between 30% – 120% in recent months.

For further information, click here

Bionaturis turns two years on the MAB: 3, 2, 1… ready to take off!

It is just two years ago that Bionaturis started quoting on the Spanish Alternative Stock Market (MAB). On 26th January, 2012; the managers of the company began the new age ringing the bell at the opening session of its quotation. Since then, Bionaturis has had an exponential growth and the future prospects can’t be better, as our general manager, Javier Gallastegui, states.

-How do you remember the IPO process and Bionaturis’ opening day at MAB?

-My arrival at the company was in a key moment because I started to work at Bionaturis very little time before trading at the MAB, so, the process was already ongoing. About that day, I remember moments of great happiness, with emotion and pride shared with our team, which was there all together. We realized how well-known people both in the industry and the financial sector, among them my closest guests, looked with admiration at such an important milestone we were achieving.  Among them Emilio Moraleda, who joined our Board of Directors shortly after that.

-What has the MAB provided to Bionaturis’ development these two years?

-Apart from the logical contribution as source of capital income, for our development and current position being a transparent trading company for the lens of our multinational customers, our investors and the stock market is very important. The experience and the balance, according to facts and results, can’t be more positive: the company market cap has more than doubled since then and so our multinational clients and product portfolio as well. The future is bright ahead of us.

-How do you describe the current situation of Bionaturis on the MAB?

-With a great strength, and as it’s usual to say in these cases, I am not the person who […]

Bionaturis contributes in the MAB’s take off year

2013 will go down into history of the recently founded Alternative Spanish Stock Market (MAB) as the year in which it confirmed its take off increasing the trading volume by five fold. According to statistics published by BME, it has reached 279 million € in volume and 87 million of stock transactions.

The 23 companies listed on the MAB –among them, Bionaturis- have raised 45 million euros in the market, +12% from 2012. Last year, there were 13 capital increases and the number of trades increased by eight fold. The overall market capitalization at the end of 2013 reached 1.677 million euros, three times more than in the previous year.

The specialized media Cinco días claims Carbures as the company that has registered the top performance in the past year with 710% increase. It has been followed by other companies, accounting Gowex (nearly 500%), Ebios (148%) and Bionaturis itself, ended up the year with a global 110% rise.

2014 for the MAB has begun in an encouraging way in their first sessions, while companies are willing to continue breaking records.

At the begining of the new year, let’s go over the main events for Bionaturis during 2013

As it was forecasted in the business plan, 2013 has been full of activity for Bionaturis, with a much than positive balance in a key area for our business model: the relationship with multinational companies. Thus, during last year Bionaturis has released the signing of three contracts with important veterinarian multinational companies to test its vaccines, such as the one intended to prevent the most devastating diseases of salmons, or the unique vaccine that fight helmints infections in livestock. These agreements have confirmed its position as a global supplier of biological vaccines.

This remarkable position was endorsed in September with the organization, along with “Corporation Tecnologica de Andalucia”, of the Biotech Technical Committee. The event, gathering managers of large laboratories and international experts in the field, was part of the Flylife’s gala day, a manufacturing facility showing one of the highest ratio of biological product production by square meter currently in the market.

In the institutional side, we also highlight that the prestigious Forbes magazine in its last March edition named our CEO, Victor Infante, as one of the 25 young businessmen in Spain to be tracked. Later, in October, he was invited to the extraordinary executive committee of the “Confederation Empresarios de Cadiz”, being chaired by in this special occasion by His Royal Highness Prince Felipe de Asturias, where Infante explained to the attendees the principles, mission and vision of Bionaturis.

2013 has also brought striking news for our investors, ending up the year with a +110% of the annual share price and a remarkable increase of the daily trading volume. That situation has led the BNT-MAB titles to be included in different proposals of investment portfolios for 2014 and it is considered one of the […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR